Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Generic Benchmarking: Brand Erosion at Patent Expiry

Generic Benchmarking: Brand Erosion at Patent Expiry

Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.

Scope

*Understand brand erosion according to formulation, therapy area and brand value in the seven major markets

*Analysis of the top 10 most eroded brands during Q2 2006 and Q2 2008

*Overview of prices of generic drugs in the seven major markets

*Case studies of successful and unsuccessful strategies to protect the branded franchise

Highlights

Tough competition, a focus on cost-containment and incentives for prescribing generic drugs, make the US, UK and Germany prone to severe brand erosion immediately after patent expiry. The US saw the strongest erosion for both oral and injectable drugs, reflecting the high level of generic substitution in the US compared to other markets.

Across all markets, the higher the annual sales of a branded drug, the more intense its generic erosion at patent expiry. Competition among generic players targeting high value drugs is also fierce, leading to a rapid decline in generic prices as more players enter the market.

Overall, the most heavily eroded drugs by therapy area in the US were respiratory drugs, due to the large market size and low entry barriers for generics companies, while CNS drugs experienced the lowest levels of erosion.

Reasons to Purchase

*Identify the different factors that drive brand erosion in the seven major markets in the first 2 years of generic entry

*Understand the average level of erosion a brand can expect to face following generic incursion, depending on its formulation, value and ATC group

*Evaluate the success of various reformulation strategies in protecting brand franchise from generic competition

12-Mar-09 PDF & SlidePack Pages: 93

Table of Contents
Price: $7,600.00 / €5,079.84

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions